Home › Funds › BOONE CAPITAL MANAGEMENT LLC › CGEM
BOONE CAPITAL MANAGEMENT LLC position in CGEM
CULLINAN THERAPEUTICS INC · Health Care
BOONE CAPITAL MANAGEMENT LLC reported holding 690,814 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$10.6M, representing 2.81% of its reported portfolio and ranking #14 among its reported holdings. BOONE CAPITAL MANAGEMENT LLC has disclosed CGEM holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How BOONE CAPITAL MANAGEMENT LLC's CGEM position evolved
BOONE CAPITAL MANAGEMENT LLC first disclosed a stake in CGEM in Q2 2026 at 704,442 shares (US$12.8M). Across 2 filings, BOONE CAPITAL MANAGEMENT LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 690,814 shares valued at US$10.6M — a reduction of -13,628 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 704.44K | $12.83M | New |
| Q3 2026 | 690.81K | $10.60M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGEM and 13F data
CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 31 other funds we track also report a position in CGEM — the largest reported positions include MPM BioImpact LLC (US$149.2M), Lynx1 Capital Management LP (US$137.6M), BVF INC/IL (US$88.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGEM
- MPM BioImpact LLC 9.72M sh · $149.22M · Q3 2026
- Lynx1 Capital Management LP 8.96M sh · $137.59M · Q3 2026
- BVF INC/IL 5.75M sh · $88.27M · Q3 2026
- Kynam Capital Management, LP 3.11M sh · $47.80M · Q3 2026
- RTW INVESTMENTS, LP 2.36M sh · $36.29M · Q3 2026
- Siren, L.L.C. 1.79M sh · $27.53M · Q3 2026
- Blue Owl Capital Holdings LP 1.40M sh · $21.49M · Q3 2026
- Venrock Adviser, LLC 1.38M sh · $21.18M · Q3 2026
- Elmind Capital, LP 962.79K sh · $14.78M · Q3 2026
- Affinity Asset Advisors, LLC 875.76K sh · $13.44M · Q3 2026
- TWIN FOCUS CAPITAL PARTNERS, LLC 595.49K sh · $9.14M · Q3 2026
- Boxer Capital Management, LLC 450.00K sh · $6.91M · Q3 2026
More on BOONE CAPITAL MANAGEMENT LLC
FAQ
How long has BOONE CAPITAL MANAGEMENT LLC held CGEM?
BOONE CAPITAL MANAGEMENT LLC has disclosed CGEM holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is BOONE CAPITAL MANAGEMENT LLC's current position in CGEM?
As of Q3 2026, BOONE CAPITAL MANAGEMENT LLC holds 690.81K shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $10.60M, representing 2.81% of its reported portfolio and ranking #14.
Has BOONE CAPITAL MANAGEMENT LLC been buying or selling CGEM?
In the latest 13F filing (Q3 2026), BOONE CAPITAL MANAGEMENT LLC reduced its position in CGEM.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, BVF INC/IL, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.